Scarica l'app Stockscreener
1.10
1.85%
0.02
Dopo l'orario di chiusura:
1.10
Precedente Chiudi:
$1.08
Aprire:
$1.08
Volume 24 ore:
14,471
Relative Volume:
0.27
Capitalizzazione di mercato:
$10.84M
Reddito:
-
Utile/perdita netta:
$-18.98M
Rapporto P/E:
-0.3855
EPS:
-2.8535
Flusso di cassa netto:
$-14.55M
1 W Prestazione:
-5.17%
1M Prestazione:
+12.72%
6M Prestazione:
-39.23%
1 anno Prestazione:
-42.41%
Intervallo 1D:
$1.08
$1.11
Intervallo di 1 settimana:
$1.08
$1.22
Portata 52W:
$0.88
$2.73
In 8 Bio Inc Stock (INAB) Company Profile
Nome
In 8 Bio Inc
Settore
Industria
Telefono
(646) 600-6438
Indirizzo
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.10 | 10.65M | 0 | -18.98M | -14.55M | -2.8535 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-18 | Iniziato | Laidlaw | Buy |
| 2022-08-30 | Iniziato | H.C. Wainwright | Buy |
In 8 Bio Inc Borsa (INAB) Ultime notizie
KALA BIO (NASDAQ: KALA) sets Sept. 19 cutoff for 2026 shareholder proposals - stocktitan.net
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure - BioSpace
GRI Bio posts Phase 2a IPF biomarker and safety data; +99 mL placebo‑adj FVC, supports longer study - TradingView
Experimental IPF pill from GRI Bio (GRI) boosts lung function in 12 weeks as company eyes 52-week study - stocktitan.net
Cough during treatment was 0% with GRI Bio's drug, versus 25% on placebo - stocktitan.net
symbol__ Stock Quote Price and Forecast - CNN
Investor group in Valion Bio (VBIO) shifts to passive stake - Stock Titan
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
Valion Bio Raises $7.74 Million Via Series B/C Preferred and Warrants From 3i - TradingView
2,426,857 Boundless Bio (NASDAQ: BOLD) shares held by Zachary Hornby - Stock Titan
KALA BIO Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Valion Bio, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Valion Bio (VBIO) holder nears 10% after big preferred swap - Stock Titan
Gossamer Bio Lines Up Up To $250 Million Private Placement With Milestone-Triggered Warrants - TradingView
3i injects cash into Valion Bio (VBIO) under tight ownership cap - Stock Titan
Tech workers may be better off selling their company stock - Business Insider
TELA Bio (TELA) stake: Nantahala group reports 12.94% ownership of 5.79M shares - Stock Titan
Palisade Bio (PALI): Commodore Capital group now reports 0.0% beneficial ownership - Stock Titan
Climb Bio, Inc. (CLYM): MPM BioImpact LLC reports 0% ownership in amendment - Stock Titan
Point72 discloses 4.95% Q32 Bio Inc. (QTTB) holding in Schedule 13G/A - Stock Titan
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Q32 Bio Inc. (QTTB) major holders cut reported stake to 0% - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q2 2026 loss and extends cash runway - Stock Titan
BIO-key International (BKYI) secures $2.51M and issues 1.24M new warrants in financing - Stock Titan
Palisade Bio (PALI): Soleus group reports 7.5% stake, 13.1M shares held - Stock Titan
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Valion Bio, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares - Stock Titan
Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares - Stock Titan
BRVE SEC FilingsBraveheart Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy - Yahoo Finance
Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside - TradingView
Valion Bio Enters Securities Purchase Agreement With Avenue, Issues Preferred for $750,000 Milestone - tradingview.com
Climb Bio (Nasdaq: CLYM) details pipeline progress and funding into 2028 - Stock Titan
Nuvation Bio (NYSE: NUVB) posts $31.7M Q2 revenue and $62.8M loss - Stock Titan
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress - Yahoo Finance
Large equity grants for TELA Bio, Inc. (TELA) CEO Heather Getz - Stock Titan
Q32 Bio reports Q2 2026 net loss $8.9M, cash $106.3M and $200M July offering - TradingView
Q32 Bio Inc. 2Q 2026: Net loss $(8.95)M, EPS $(0.44) — 10-Q Summary - TradingView
Q32 Bio (Nasdaq: QTTB) reports AA trial gains and $200M raise - Stock Titan
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX) - Stock Titan
Heather Getz named CEO of TELA Bio as Antony Koblish exits - TradingView
Vanguard Capital Management (CABA) discloses 8.30M-share passive stake in Cabaletta Bio - Stock Titan
Tevogen Inc. (NASDAQ: TVGN) changes name from Tevogen Bio Holdings - Stock Titan
BlackRock (PALI holder) discloses 6.0% ownership of Palisade Bio common stock - Stock Titan
Tevogen Bio Holdings Inc. Becomes Tevogen Inc. - GlobeNewswire
In 8 Bio Inc Azioni (INAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):